Follow the Eupraxia Pharmaceuticals Inc. stock price and the full insider trade history of the company, a listed issuer based in Canada. Shares are quoted on the CA market, under the authority of SEDI. Market capitalisation: €626.1m. The latest transaction was disclosed on 19 August 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Pott, Amy. Every trade is openly available.
37
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Eupraxia Pharmaceuticals Inc. Strong Buy (bullish), based on 2 analysts. Average price target: CA$16.00.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
104,500 shares@ CA$8.6320.7% of flowRights Restricted Stock UnitTSXSEDI:4627035
25 of 37 declarations
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative treatments for inflammatory diseases and musculoskeletal disorders. It is listed on the XTSE market.